Member Sign In

You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.

If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.

Healthcare ETFs: Gain or Pain Ahead in Q3 Earnings?

The Q3 earnings season is in full swing with the healthcare sector showing the third highest growth at this stage, trailing materials and business services. Earnings from 22% of the sector’s market capitalization that have reported so far are up 15.9% with a beat ratio of 83.3% on revenue growth of 8.8% and revenue surprise of 66.7%, as per the Earnings Trends.

Let’s delve into the earnings picture of some of the other largest companies in the healthcare space that would drive the performance of the above-mentioned funds in the coming days. Some of the big names include Pfizer (PFE - Free Report) , Merck (MRK - Free Report) , Amgen (AMGN - Free Report) , AbbVie (ABBV - Free Report) , Gilead Sciences (GILD - Free Report) and Bristol-Myers Squibb Company (BMY - Free Report) that dominate these fund’s portfolio. All these stocks collectively account for the maximum portion, with 28.6% share in XLV, 27.4% in IYH, 25% in VHT and 24.6% in FHLC.

Inside Our Surprise Prediction of These Stocks

Pfizer has a Zacks Rank #3 (Hold) and an Earnings ESP of -1.59%, indicating a lower probability of beating estimates this quarter. According to the our surprise prediction methodology, a Zacks Rank #1 (Strong Buy), #2 or #3 when combined with a positive Earnings ESP has chances of an earnings beat, while a Zacks Rank #4 or #5 (Sell rated) are best avoided. Pfizer delivered positive earnings surprises in the last four quarters, with an average beat of 11.16%.

Additionally, the Zacks Consensus Estimate for third-quarter 2016 is 63 cents, up a penny over the past three months. Further, the stock has a solid Value and Momentum Style Score of B and A, respectively, while a Growth Style Score of C looks unimpressive. Pfizer is scheduled to report its earnings on November 1 before the opening bell.

Merck is expected to report its results on October 25 before market open. It has a Zacks Rank #2 (Buy) and an Earnings ESP of 0.00%, which makes surprise prediction difficult. The stock saw no earnings estimate revision over the past 90 days for the to-be-reported quarter. The drug maker delivered positive earnings surprises in the last four quarters, with an average beat of 3.37%. The stock has an unfavorable Value and Growth Style Score of C and D, respectively, while a Momentum Style Score of B looks good (read: 5 ETFs to Buy as Election Uncertainty Looms).

Amgen has a Zacks Rank #3 and an Earnings ESP of +1.08%, indicating a good chance of beating estimates this quarter. The earnings surprise track over the past four quarters is robust with an average positive surprise of 11.55%. The stock also witnessed positive earnings estimate revision of a penny over the past 90 days for the yet-to-be-reported quarter. Additionally, the stock has a solid Value Style Score of B but an unfavorable Growth and Momentum Style Score of C and D, respectively. Amgen will reports its earnings on October 27 after market close.

AbbVie has a Zacks Rank #3 and an Earnings ESP of +0.83%, indicating a reasonable chance of beating estimates this quarter. The company delivered positive earnings surprises in the last four quarters, with an average beat of 3.32%. Moreover, it saw solid positive earnings estimate revision of three cents over the past three months for the to-be-reported quarter. Further, the stock has a top Momentum Style Score of A and a Value Style Score of B while the Growth Style Score is unimpressive at C. The company is schedule to report on October 28 before market open.

Gilead is expected to release its earnings on November 1 after market close. It has a Zacks Rank #5 (Strong Sell) and an Earnings ESP of -0.36%. Gilead saw a negative earnings estimate revision of 19 cents over the past three months for the to-be-reported quarter but delivered positive earnings surprises in three of the last four quarters, with an average beat of 4.08%. Though it has a solid Value and Growth Style Score of B each, the Momentum Style Score of F is an eyesore (read: Prepare for a Clinton Presidency with These Stocks & ETFs).

Bristol-Myers will likely report its earnings on October 27 before the opening bell. It has an unfavorable Zacks Rank #4 but an Earnings ESP of +3.08%. The stock delivered positive earnings surprises over the past four quarters with an average beat of 15.56% and saw positive earnings estimate revision of a penny for the to-be-reported quarter. However, it has an unfavorable Value, Growth and Momentum Style Score of C, F and C, respectively.

Summing Up

Given that some companies have an unfavorable Zacks Rank and a lower probability of beating this quarter, healthcare ETFs might struggle to hold onto gains in the coming days. However, the above-mention ETFs have a favorable Zacks ETF Rank of #1 (Strong Buy) in case of XLV, VHT and IYH and #2 for FHLC (see: all the Healthcare ETFs here).

Want key ETF info delivered straight to your inbox?

Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>

Resources

Client Support

Follow Us

Zacks Moblie App

Zacks Research is Reported On:

Yahoo

MSN

Marketwatch

Nasdaq

Forbes

Investors.com

Morningstar

Copyright 2018 Zacks Investment Research

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +25% per year. These returns cover a period from 1988-2017. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zack Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.

Visit performance for information about the performance numbers displayed above.